Kenneth P Olive
Overview
Explore the profile of Kenneth P Olive including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
7466
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wasko U, Jiang J, Dalton T, Curiel-Garcia A, Edwards A, Wang Y, et al.
Nature
. 2024 Nov;
635(8040):E12.
PMID: 39533066
No abstract available.
2.
Carpenter E, Vendramini-Costa D, Hasselluhn M, Maitra A, Olive K, Cukierman E, et al.
Cancer Res
. 2024 Sep;
84(21):3505-3508.
PMID: 39283867
Pancreatic ductal adenocarcinoma is a deadly disease and is projected to become the second leading cause of cancer-related death by 2030. A major hallmark is the exuberant host response comprising...
3.
Safari M, Scotto L, Basseville A, Litman T, Xue H, Petrukhin L, et al.
bioRxiv
. 2024 Jul;
PMID: 39005268
Statement Of Significance: Pancreatic ductal adenocarcinoma, a significant clinical challenge, could benefit from the latent potential of epigenetic therapies like HDAC inhibitors-(HDIs), typically limited to hematological malignancies. Our study shows...
4.
Decker-Farrell A, Sastra S, Harimoto T, Hasselluhn M, Palermo C, Ballister E, et al.
bioRxiv
. 2024 May;
PMID: 38746175
Pancreatic ductal adenocarcinoma (PDAC) poses significant challenges for effective treatment, with systemic chemotherapy often proving inadequate due to poor drug delivery and the tumor's immunosuppressive microenvironment. Engineered bacteria present a...
5.
Wasko U, Jiang J, Dalton T, Curiel-Garcia A, Edwards A, Wang Y, et al.
Nature
. 2024 Apr;
629(8013):927-936.
PMID: 38588697
Broad-spectrum RAS inhibition has the potential to benefit roughly a quarter of human patients with cancer whose tumours are driven by RAS mutations. RMC-7977 is a highly selective inhibitor of...
6.
Damoci C, Merrill J, Sun Y, Lyons S, Olive K
Cold Spring Harb Perspect Med
. 2024 Mar;
14(11).
PMID: 38503500
The broad application of noninvasive imaging has transformed preclinical cancer research, providing a powerful means to measure dynamic processes in living animals. While imaging technologies are routinely used to monitor...
7.
Raufi A, Pellicciotta I, Palermo C, Sastra S, Chen A, Alouani E, et al.
bioRxiv
. 2024 Jan;
PMID: 38234792
Purpose: The CXCL12-CXCR4 chemokine axis plays a significant role in modulating T-cell infiltration into the pancreatic tumor microenvironment. Despite promising preclinical findings, clinical trials combining inhibitors of CXCR4 (AMD3100/BL-8040) and...
8.
Wasko U, Jiang J, Curiel-Garcia A, Wang Y, Lee B, Orlen M, et al.
bioRxiv
. 2023 Dec;
PMID: 38105998
Broad-spectrum RAS inhibition holds the potential to benefit roughly a quarter of human cancer patients whose tumors are driven by RAS mutations. However, the impact of inhibiting RAS functions in...
9.
Hasselluhn M, Decker-Farrell A, Vlahos L, Thomas D, Curiel-Garcia A, Maurer H, et al.
Cancer Discov
. 2023 Nov;
14(2):348-361.
PMID: 37966260
Significance: We present a key mechanism of tumor angiosuppression, a process that sculpts the physiologic, cellular, and metabolic environment of PDAC. We further present a computational and experimental framework for...
10.
Decker-Farrell A, Ma A, Li F, Muir A, Olive K
STAR Protoc
. 2023 Nov;
4(4):102711.
PMID: 37950862
Traditional 2D/3D co-culture models typically do not reflect the cellular heterogeneity of pancreatic ductal adenocarcinoma (PDAC) tumors, while in vivo models can be slow and ill-suited to mechanistic investigations. Here,...